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Human herpesvirus 6 (HHV-6) is a lymphotropic betaherpesvirus which productively infects human CD41
T cells and monocytes. HHV-6 is the etiologic agent for exanthem subitum (roseola), and it is well-known that
central nervous system complications occur frequently during the course of HHV-6-associated disease. In
addition, HHV-6 has been associated with encephalitis or encephalopathy. However, very little is known about
its tropism for neural cells. There are reports that HHV-6 may infect some glial cell lines, but whether it can
infect any primary neural cells is not known. Our studies show that both HHV-6A (GS) and HHV-6B (Z-29)
can infect highly purified primary fetal astrocytes in vitro. Infected cells showed cytopathic effects, forming
giant syncytia. In dual immunofluorescence assays, the infected cells were detected by antibodies against the
HHV-6 p41 nuclear antigen and glial fibrillary acidic protein, indicating that the infected cells are indeed
astrocytes. PCR and Northern (RNA) blot analyses also confirmed that the astrocytes are infected by HHV-6.
The progeny virus did not alter its host range and could reinfect T cells as well as primary astrocytes. These
findings suggest that infection of primary human astrocytes may play a role in the neuropathogenesis of
HHV-6.
Human herpesvirus 6 (HHV-6) is a recently discovered lym-
photropic betaherpesvirus (3) which has been identified as the
etiologic agent for exanthem subitum (roseola) (35) and as a
major cause of acute febrile illness in young children (17, 27).
HHV-6 isolates can be differentiated into two groups, variants
A and B, on the basis of antigenic specificity, genetic polymor-
phism, and in vitro growth properties (1). Variant A isolates
include those that were isolated from adults, such as the pro-
totype GS strain that was isolated from a patient with a lym-
phoproliferative disorder (29). HHV-6 variant group B con-
sists of most of the isolates from children with exanthem
subitum (3, 12), but it also includes some isolates from adults,
such as the prototype Z-29 strain isolated from a Zairian AIDS
patient (7). HHV-6 has been implicated as an important co-
factor in AIDS; it can infect many of the same cell types as
human immunodeficiency virus type 1 (HIV-1), such as CD41
T cells (2), and it can enhance replication of HIV and the
cytopathic effects in cells that are dually infected by HIV and
HHV-6 (14). HHV-6 has been shown to transactivate HIV
regulatory elements (14, 18, 34), up-regulate CD4 antigen ex-
pression, and expand the host range for HIV infection (24). In
addition, other studies have shown that HHV-6 can suppress
the replication of HIV-1 in coinfected cells (8, 22). Recent
attention has also focused on the roles of HHV-6 in causing
neurological disease (23, 33). It has been suggested that
HHV-6 invades the central nervous system (CNS) during ac-
tive infection. HHV-6 DNA has been detected in the cerebro-
spinal fluid from patients with exanthum subitum, especially
from those with febrile convulsive seizures (9, 21, 36). HHV-6
sequences have also been detected in CNS specimens from
patients with multiple sclerosis, but the significance of finding
sequences in multiple sclerosis patients is controversial (10,
31). HHV-6 has been associated with encephalitis or enceph-
alopathy (5, 13, 19, 20, 32), with possible latent infection of the
CNS (9), and with reactivation to cause febrile convulsions
(17).
In spite of the neurological complications associated with
HHV-6 infection, very little is known about its tropism for
neural cells. Two reports have described the detection of
HHV-6 in human brain tissues associated with fatal encepha-
litis (5, 13). More recently HHV-6 was detected in four of five
children with HIV-1 encephalitis by in situ hybridization of
postmortem brain tissues (28). HHV-6 signals were found in
numerous oligodendrocytes and less frequently in astrocytes,
microglia, and neurons (28). These recent studies suggest that
HHV-6 infection of the CNS may play an important role in the
neuropathogenesis of HIV-1 infection. Thus, there is a need to
establish cell culture models to study HHV-6 infection of neu-
ral cells in vitro, and it is important to determine the cell types
that are permissive for HHV-6 infection in the CNS.
A previous report has suggested that HHV-6 can abortively
infect a glioblastoma cell line in vitro (4), but it has not been
determined whether HHV-6 can infect any nontransformed,
neuroepithelium-derived cells. In this study, we have tested the
infectivity of HHV-6 in nontransformed human astrocytes. As-
trocyte cultures used for HHV-6 infection were prepared from
first-trimester human fetal specimens (46 to 83 days of gesta-
tion). Fetal CNS tissue was obtained from the Human Embry-
ology Laboratory, University of Washington, Seattle. Proce-
dures for procurement and use of this human fetal CNS tissue
were approved and monitored by the University of Miami
School of Medicine’s Medical Sciences Subcommittee for the
Protection of Human Subjects. The CNS tissue from each fetal
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specimen was processed separately and independently, as were
subsequent cell cultures; there was no pooling of CNS tissue
from distinct fetal specimens. These cells were grown in a
serum-free, defined medium (B16) enriched with 5 ng of basic
fibroblast growth factor per ml for optimal growth of astrocytes
and for the suppression of fibroblast growth (Fig. 1A) (25). By
immunofluorescence assay, these cultures homogeneously ex-
pressed glial fibrillary acidic protein (GFAP), the definitive
marker for astrocytes (Fig. 1B). Most importantly, cultures
expressed little or no fibronectin or prolyl hydroxylase, both
markers for fibroblasts (Fig. 1C). Fewer than 50 fibronectin-
positive cells could be counted per 10,000 GFAP-positive cells.
Moreover, cultures continued to express GFAP with little or
no fibronectin when monitored at each subculture and during
HHV-6 infection. With supplemented B16 medium we were
able to maintain highly purified human fetal astrocyte cultures,
allowing subsequent unambiguous experimental determination
of HHV-6 growth in astrocytes in vitro.
Human primary astrocytes can be infected by HHV-6. In
order to study the susceptibility of astrocyte cultures to HHV-6
infection, the astrocytes were either cocultivated with
HHV-6A strain GS-infected HSB-2 T cells (HSB-2/GS) or
infected with cell-free GS virus at a 103 50% tissue culture
infective dose (TCID50)/10
6 cells. For coculture, the astrocytes
were incubated with HHV-6-infected HSB-2 T cells at a 1:1
ratio overnight and then washed extensively to remove the T
cells. For cell-free HHV-6 infection, the astrocytes were incu-
bated with the cell-free virus for 2 h at 378C, washed three
times with phosphate-buffered saline, and cultured with astro-
cyte medium. Astrocytes that were either cocultivated with
HSB-2/GS or infected with cell-free GS virus formed giant
syncytia with multiple nuclei (Fig. 2A), indicating that HHV-6
infection of astrocytes induces cell fusion and cytopathic ef-
fects. In the cocultivated cultures, syncytia tended to appear
more quickly than in the GS-infected cultures and numerous
syncytia could be observed within 2 days. The cultures that
were infected by cell-free virus developed syncytia more slowly
but usually by 3 days postinfection. Similar results were ob-
tained with HHV-6B strain Z-29 (data not shown). However,
with HHV-6B Z-29, the titer of the viral stock used was about
100-fold lower than that of GS, and only a 101.7 TCID50/10
6
cells was used for infection. For Z-29 infection compared with
HHV-6A, fewer syncytia and less cytopathic effect were ob-
served, perhaps because of the lower titer of the input Z-29
viral stock. Alternatively, Z-29 infection of the astrocytes may
be less efficient.
To confirm infection of the astrocytes by HHV-6, an immu-
nofluorescence assay for specific viral antigens was performed.
Cultures that were infected by cell-free GS or Z-29 were fixed
with paraformaldehyde (25) at 5 days postinfection and then
analyzed with a monoclonal antibody against an HHV-6 early
nuclear antigen, p41 (11, 16). Most of the staining appeared to
be localized to the syncytia, and the multinuclei were very
brightly stained (Fig. 2B). Scattered individually stained cells
also appeared throughout the culture, suggesting that there are
many more infected cells than those that formed syncytia. The
infected cells were simultaneously stained with an anti-GFAP
polyclonal antibody. The astrocyte cultures, including the in-
fected cells, expressed GFAP, indicating that the infected cells
are indeed astrocytes (Fig. 2C). However, GFAP staining was
weaker in syncytia, and there appeared to be condensation of
GFAP-containing intermediate filaments. Infection was also
monitored by another monoclonal antibody, 2D6, specific
against the HHV-6 surface glycoprotein gp82-gp105 (6). In-
fected cells showed diffuse surface staining of the cytoplasm,
both in cells forming syncytia and in single cells (data not
FIG. 1. Human astrocyte cultures at third passage derived from rostral CNS
tissue maintained in B16 medium supplemented with basic fibroblast growth
factor. (A) Phase-contrast micrograph; (B) immunofluorescence staining of as-
trocyte culture for GFAP; (C) immunofluorescence staining for fibronectin.
Primary antibodies included rabbit polyclonal anti-GFAP (DAKO, Carpinteria,
Calif.) and mouse monoclonal anti-human fibronectin (Boehringer Mannheim,
Indianapolis, Ind.). Secondary antibodies included goat anti-rabbit immunoglob-
ulin G conjugated to rhodamine and goat anti-mouse immunoglobulin G con-
jugated to fluorescein (both from Boehringer Mannheim). Magnification, 3110.
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shown). Our immunofluorescence studies thus suggest that
viral proteins, including both early and late gene products,
were expressed in astrocytes that are infected by HHV-6. To
determine further the viral protein expression, uninfected and
cell-free HHV-6A (GS)-infected astrocytes were labeled with
[35S]methionine for 20 h, and at 7 days postinfection, lysates
were used for radioimmunoprecipitation reactions with various
HHV-6A monoclonal antibodies according to methods de-
scribed previously (6). Monoclonal antibodies immunoprecipi-
tated viral early proteins and glycoproteins from infected cells
(data not shown), thus confirming viral replication in astro-
cytes.
Molecular analyses of HHV-6-infected cells. To further con-
firm infection of the astrocyte cultures by HHV-6, DNA was
extracted 7 days postinfection from astrocytes that were in-
fected with cell-free HHV-6 and analyzed for HHV-6 se-
quences by PCR. The infected cells were digested with 0.05%
trypsin-EDTA and then with 5 U of DNase for 30 min at 378C
before DNA extraction in order to eliminate virus particles
adsorbed onto the surface of the cells. The purified DNA was
then tested for the presence of an immediate-early gene B701
(16) of HHV-6 by PCR (15). The sequence of this gene is
conserved between both A and B strains (34), and the primer
set should amplify a 460-bp fragment (Fig. 3). The primer set
used was 59-TACATTATGAAGTCTTGC-39 and 59-CTCA
AAGTATGACGTATC-39, and the reaction conditions were,
for 30 cycles, 948C for 1 min, 508C for 1 min, and then 728C for
2 min. DNA extracted from HHV-6A strain GS-infected as-
trocytes showed an intense PCR-amplified band of 460 bp;
similar bands were detected in DNA obtained from GS-in-
fected HSB-2 T cells, HHV-6B strain Z-29-infected astrocytes,
Molt-3 T cells, and purified HHV-6A strain U1102 viral DNA.
No viral DNA was detected in mock-infected astrocytes or
Molt-3 T cells. Even though the PCR amplification performed
was not quantitative, much more viral DNA was amplified
from GS-infected astrocytes than from Z-29-infected cells
when the same total number of infected cells were used (Fig.
3). This result is consistent with our infectivity studies, which
show less extensive cytopathic effect with Z-29.
Northern blot analyses of HHV-6-infected astrocytes. To
further confirm that HHV-6 genes are expressed in infected
astrocytes, Northern (RNA) blot analysis was carried out with
the p41 early gene probe (11, 16, 37). The p41 gene codes for
an accessory protein which binds to viral DNA polymerase (11,
16, 37). Multiple RNA species are transcribed from this gene
FIG. 2. Human astrocyte cultures at 5 days postinfection with 103 TCID50 of
HHV-6 GS. (A) Phase-contrast micrograph of the infected culture showing giant
multinucleated syncytia; (B) immunofluorescence staining of infected cells with
monoclonal antibody against p41 nuclear protein of HHV-6; (C) immunofluo-
rescence staining of infected culture shown in panel B for GFAP. Secondary
antibodies are described in the legend to Fig. 1. Magnification, 3100 (A) and
3220 (B and C).
FIG. 3. PCR amplification of HHV-6 B701 gene fragment from total DNA
extracted from various infected astrocyte cultures and T-cell lines. The cultures
were infected with cell-free HHV-6, and the amplified product was analyzed on
a 1.2% agarose gel. The 0.46-kb product (indicated on the left) represents the
amplified B701 gene fragment. Astrocyte (GS) and astrocyte (Z-29) represent
DNA extracted from astrocytes infected with cell free HHV-6 strains GS and
Z-29, respectively. DNA from T-cell lines HSB-2 and Molt-3 infected by GS and
Z-29, respectively, and HHV-6A strain U1102 viral DNA were used as positive
controls. Mock and Molt-3 represent DNA from uninfected astrocytes and T
cells, respectively.
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locus. Five different RNA species, with sizes of 2.3, 1.8, 1.5, 1.2,
and 0.8 kb, were detected in GS-infected HSB-2 T cells. Sim-
ilar RNA species were detected in cell-free GS-infected astro-
cyte cultures (Fig. 4A). On Northern blots, the intensity of the
hybridized RNA species was much weaker in the extracted
RNA from infected astrocytes than in an equivalent amount of
RNA from T cells. This difference again suggests that infection
or viral RNA expression was less efficient in astrocytes than in
T cells. In spite of weaker signals, the viral RNA species ex-
pressed are identical for both cell types, suggesting that there
are no gross differences in the p41 viral gene expression be-
tween the two cell types.
Since expression of the p41 gene may not necessarily indi-
cate that HHV-6 can actively replicate and express viral late
genes in the infected astrocytes, Northern blot analysis with a
late HHV-6 gene that encodes for the envelope-gp105 protein
was also performed. This gene is expressed late in infection,
and multiply spliced RNA species are expressed in this locus
(26). The hybridization pattern of the RNA extracted from
cell-free HHV-6A GS-infected astrocytes with the gp105 probe
was similar to that from GS-infected HSB-2 T cells (Fig. 4B).
Four different RNA species, with sizes of 3.9, 3.0, 2.1, and 1.6
kb, were detected. These four RNA species represent the mul-
tiply spliced RNA expressed from this locus late in infection
(26). However, the 1.0-kb RNA species found in T cells were
not detected in the infected astrocytes, suggesting either that
the level of expression was too low to be detected or that there
may be differences in splicing and posttranscriptional modifi-
cations of the RNA for this gene in different cell types. Nev-
ertheless, the detection of spliced RNA strongly suggests that
active viral replication can occur in GS-infected astrocytes.
Replication kinetics of HHV-6 in astrocytes. To demonstrate
that infectious HHV-6 virus was produced by the infected
astrocyte cultures, cells were infected with cell-free HHV-6A
(GS) at a concentration of 103 TCID50/10
6 cells. The infected
cells were washed and then incubated in culture medium at
378C. Supernatants from these infected cell cultures, contain-
ing cell-free virus, were collected at 1, 4, and 7 days postinfec-
tion, and the infectious titer of the virus was determined in
HSB-2 indicator cells (Fig. 5) (30). No virus was detected at
day 1 postinfection. The titer of the cell-free virus from the
infected culture then increased with time, with about 101.5
TCID50/ml at day 4 postinfection and 10
2.5 TCID50/ml at day 7
postinfection. The infectious titer of cell-free virus was not
determined after day 7 postinfection because the cumulative
cytopathic effect destroyed the infected astrocytes. The kinetics
of viral production corresponded well with the development of
syncytia; syncytia were not detected at day 1 postinfection but
started to appear at day 3 postinfection. Massive syncytia and
cell death usually occurred by about 7 days postinfection. The
increases in virus titer and cytopathic effects with time strongly
suggest that infectious virus was produced in astrocytes as a
result of active HHV-6 replication. The ability of the viruses
from the astrocyte culture to reinfect T cells indicates that the
host range specificity of HHV-6 has not been altered by pas-
saging through astrocytes. Nevertheless, the titer of virus ob-
tained from the infected astrocyte cultures is about 100-fold
lower than the quantity of HHV-6A (GS) obtained from T
cells (HSB-2 or J-Jhan) with similar TCID50 inoculum doses
and infection procedures. This lower virus titer is consistent
with the level of viral gene expression as detected by PCR and
Northern blot analyses. Previous studies have shown that
HHV-6 infection of a glioblastoma cell line leads to a noncy-
topathic infection with a transient low level of viral synthesis
(4). In contrast, infection of our nontransformed, low-passage
astrocyte cultures with HHV-6 led to a productive cytopathic
infection. It is not clear at this point whether latent infection
may occur, but our results indicate that the effects of HHV-6
infection in transformed cell lines may not necessarily reflect
those that may occur in primary or nontransformed cell cul-
tures or in vivo. It will also be important to determine if
primary human neurons and/or human oligodendrocytes can
be infected by HHV-6. Our results nevertheless suggest that
lytic infection of astrocytes may play a role in the neurological
complications seen in children with acute HHV-6 infection.
FIG. 4. Northern blot analysis of cell-free GS-infected astrocytes and HSB-2
T cells. Total RNA was analyzed on a 1.2% formaldehyde gel, transferred, and
then hybridized to a labelled HHV-6 p41 (A) or gp105 (B) probe. RNA (10 mg)
from uninfected HSB-2, astrocytes, and GS-infected astrocytes was used. For
positive control GS-infected HSB-2 cells, only 1 mg of RNA was used. The
numbers on the right represent the sizes (in kilobases) of different RNA species. FIG. 5. Estimation of HHV-6 titer produced from infected astrocytes. As-
trocytes were infected with 103 TCID50 of cell-free HHV-6A (GS) virus, and the
viral titer was determined at 1, 4, and 7 days postinfection by using HSB-2 T cells
as the indicator cells. Each time point represents results from at least three
independent experiments; error bars indicate standard deviations. The titer is
expressed as log TCID50/ml of culture supernatant from the infected astrocyte
culture.
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